$30 Billion Hepatitis C Market: Drug Development Pipeline Study, H2 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Hepatitis C: Drug Development Pipeline Study, H2 2018" report has been added to ResearchAndMarkets.com's offering.

With an estimated market value of over $30 billion by 2020, the Hepatitis C industry is considered as a rapidly growing healthcare market.

Hepatitis C pipeline comprises of 85 active drugs under active development as of June 2018. Of these, 16 drugs are in Phase 1 and 19 drugs in phase 2. Only 4 drugs progressed to Phase 3. Further, 27 drugs are in Pre-clinical stage, 18 drugs in research/discovery stages.

60 companies are developing the pipeline for Hepatitis C. Of this, GinkgoPharma Co. Ltd, Biocad CJSC, Cocrystal Pharma Inc, ARA Healthcare Pvt Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Beijing Kawin Technology Share-Holding Co., Ltd. and Achillion Pharmaceuticals, Inc. have more compounds in the pipeline. On the other hand, Presidio Pharmaceuticals, Inc, F. Hoffmann-La Roche Ltd, Ascletis, Inc. and Beijing Kawin Technology Share-Holding Co., Ltd. have the most advanced pipeline products.

Mechanism of Action of most of the therapeutic candidates is HCV NS5A Inhibitors, Immunostimulants and Immunomodulators.

The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Hepatitis C (HCV) pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Hepatitis C (HCV) pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.

Companies Mentioned

  • Akshaya Bio Inc.
  • Allachem, Llc
  • Amarna Therapeutics Bv
  • ARA Healthcare Pvt Ltd
  • Ascletis, Inc
  • Beta Pharma, Inc
  • Biocad CJSC
  • Biotron Limited
  • Bolder Biotechnology, Inc
  • Cocrystal Pharma Inc
  • Conatus Pharmaceuticals Inc
  • Dekk-Tec Inc
  • Glaxosmithkline Pharmaceuticals Ltd
  • Regulus Therapeutics Inc
  • Adaptimmune Therapeutics Plc
  • Okairos Ag
  • Immunemed, Inc
  • Inovio Pharmaceuticals Inc
  • Integrated Biotherapeutics Inc
  • IQUR Ltd.
  • JN-International Medical Corporation
  • Alios Biopharma Inc
  • Merck & Company, Inc
  • Metallopharm, Llc
  • Microbio Co., Ltd
  • Multicell Technologies Inc
  • Multicell Technologies Inc
  • Novalex Therapeutics Inc
  • Novatarg Therapeutics, Inc
  • Novatarg Therapeutics, Inc
  • Presidio Pharmaceuticals, Inc.
  • Vakzine Projekt Management Gmbh
  • Whanin Pharm Co. Ltd
  • TGV-Laboratories
  • and many more...

For more information about this report visit https://www.researchandmarkets.com/research/2g3sds/30_billion?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Infectious Diseases Drugs, Liver and Kidney Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery, Infectious Diseases Drugs, Liver and Kidney Disorders Drugs